T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.
Manish A ShahTakashi KojimaDaniel HochhauserPeter EnzingerJudith RaimbourgAntoine HollebecqueFlorian LordickSung-Bae KimMasahiro TajikaAlbert Craig LockhartHendrick-Tobias ArkenauFarid El-HajbiMukul GuptaPer PfeifferPooja BhagiaZhu Alexander CaoJared LuncefordShailaja SuryawanshiMark AyersMatthew J MartonKen KatoPublished in: Future oncology (London, England) (2022)
Aim: Investigate the relationship between response to pembrolizumab and expression of the 18-gene T cell-inflamed gene expression profile (Tcell inf GEP) or PD-L1 combined positive score (CPS) in esophageal cancer. Materials & methods: This analysis included heavily pretreated patients with advanced/metastatic esophageal/gastroesophageal junction adenocarcinoma or squamous cell carcinoma who received pembrolizumab in the single-arm, phase II study KEYNOTE-180. PD-L1 CPS was evaluated with PD-L1 IHC 22C3 pharmDx. Results: In patients with squamous cell carcinoma, trends toward enrichment for responders were observed for patients with PD-L1 CPS ≥10 tumors. In patients with adenocarcinoma, a trend was observed for Tcell inf GEP but not for PD-L1. Conclusion: Tcell inf GEP and PD-L1 CPS may enrich for responders to pembrolizumab in patients with esophageal cancer. Clinical trial registration : NCT02559687 (ClinicalTrials.gov).
Keyphrases
- squamous cell carcinoma
- locally advanced
- phase ii study
- advanced non small cell lung cancer
- clinical trial
- copy number
- genome wide
- genome wide identification
- open label
- lymph node metastasis
- small cell lung cancer
- rectal cancer
- poor prognosis
- radiation therapy
- randomized controlled trial
- study protocol
- genome wide analysis
- dna methylation
- placebo controlled